Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE

Reference is made to the announcement of Genscript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") dated 22 December 2017 in relation to the collaboration and license agreement entered into among (i) Legend Biotech USA Inc., a non-wholly-owned subsidiary of the Company ("**Legend U.S.**"), (ii) Legend Biotech Ireland Limited, a non-wholly-owned subsidiary of the Company ("**Legend Ireland**", together with Legend U.S., "**Legend**"), and (iii) Janssen Biotech, Inc. ("**Janssen**") (the "**Agreement**").

The Board is pleased to announce that Janssen has received clearance of an investigational new drug application from the U.S. Food and Drug Administration and is advancing to a phase 1B/2 clinical program (the "**Phase 1B/2 Clinical Trial**") in patients with relapsed or refractory multiple myeloma ("**MM**"), evaluating the safety and efficacy of JNJ-68284528, a Chimeric Antigen Receptor T cell ("**CAR-T**") therapy based on the Group's LCAR-B38M CAR-T technology. The Phase 1B/2 Clinical Trial is part of the collaboration between Legend and Janssen that was formed in December 2017 with the aim to develop CAR-T therapy for MM globally. Please refer to the previous announcement of the Company dated 22 December 2017 for details.

JNJ-68284528 is an autologous CAR-T therapy that targets B-Cell Maturation Antigen ("**BCMA**"), a molecule expressed on the surface of mature B lymphocytes and malignant plasma cells. The JNJ-68284528 drug product expresses an identical CAR protein as Legend's LCAR-B38M CAR-T product, which is being evaluated to determine the safety and efficacy of its use to treat patients with relapsed MM by Nanjing Legend Biotechnology Co., Ltd.* (南京傳奇生物科技有限公司), a subsidiary of the Company. The results indicate that LCAR-B38M CAR-T cells have encouraging anti-myeloma activity and suggest a positive risk-benefit profile that is intended to be further defined through continued clinical studies.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate to deal in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 30 May 2018

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*